Measurements of androgenicity. the spectrum of progestogen activity
Batzer, F.R.
Journal of Reproductive Medicine 31(9 Suppl): 848-864
1986
ISSN/ISBN: 0024-7758 PMID: 2945927 Document Number: 281701
The problem with applying information on progestogen potency obtained from biologic testing to clinical prescribing practices is that the changes in potency relate to more than progestogen dosage. The spectrum of progestogen activity is discussed, with an emphasis on the effects of the progestogens used in oral contraceptive therapy.
Document emailed within 1 workday
Related Documents
Gemzell-Danielsson, K.; van Heusden, A.M.; Killick, S.R.; Croxatto, H.B.; Bouchard, P.; Cameron, S.; Bygdeman, M. 2002: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen Human Reproduction 17(10): 2588-2593Gemzell-Danielsson, K.; van Heusden, A.M.; Killick, S.R.; Croxatto, H.B.; Bouchard, P.; Cameron, S.; Bygdeman, M. 2002: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen Human Reproduction 17(10): 2588-2593
Lobo, R.A. 1988: The androgenicity of progestational agents International Journal of Fertility 33 Suppl (Zero): 6-12
Li, X.F.; Davies, G.C.; Newton, J. 1992: A review of the effects of long-acting progestogen-only contraceptives on ovarian activity Advances in Contraception: the Official Journal of the Society for the Advancement of Contraception 8(1): 1-19
Ayuda-Pascual, R.; Llorente-Comi, Mía.; Martos-Pérez, J.; Rodriguez-Bausá, L.; Olmo-Remesal, L. 2012: Measurements of stress and family impact in the parents of children with autism spectrum disorders before and after taking part in a training programme Revista de Neurologia 54 Suppl. 1: S73-S80
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Egarter, C. 2020: Progestogen-only pills: which progestogen would be ideal Hormone Molecular Biology and Clinical Investigation 42(2): 149-151
Runnebaum, B. 1992: The androgenicity of oral contraceptives: the young patient's concerns International Journal of Fertility 37(Suppl 4): 211-217
Dinsdale, S.M.; Cole, T.M.; Zaki, F.G.; Awad, E.A. 1971: Measurements of disease activity in dermatomyositis Archives of Physical Medicine and Rehabilitation 52(5): 201-6 Passim
Sandler, M.; Littlewood, J.T.; Glover, V.; Peatfield, R.; Petty, R.; Rose, F.C. 1984: Platelet phenolsulfotransferase activity and the headache spectrum Psychopharmacology Bulletin 20(3): 539-541
Spandrio, L. 1980: Optimization and standardization of measurements of enzyme activity La Ricerca in Clinica e in Laboratorio 10(Suppl 1): 99-101
Fossaluzza, V. 1983: Proglumetacin for a wide spectrum of activity in clinical medicine Minerva Medica 74(26): 1529-1533
André, C.; Descos, L.; André, F.; Vignal, J.; Landais, P.; Fermanian, J. 1985: Biological measurements of Crohn's disease activity--a reassessment Hepato-Gastroenterology 32(3): 135-137
Biagi, G.L.; Guerra, M.C.; Barbaro, A.M.; Cantelli-Forti, G.; Rossi, T. 1975: The Rm values of newer penicillins for investigating their spectrum of antibacterial activity Bollettino della Societa Italiana di Biologia Sperimentale 51(7): 403-405
Heinrich, K.; Herrmann, G. 1971: Clinical study on the activity spectrum of noxiptilin in depressive patients Arzneimittel-Forschung 21(5): 602-606
Klygul', T.A.; Garibova, T.L.; Vikhliaev, I.I. 1975: Experimental characteristics of the spectrum of pharmacologic activity of the tranquilizer lorazepam Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 75(3): 435-438